In clinical trials* involving more than 11,000 high-risk ACS patients^1-4

*See Key AGGRASTAT Studies section
Adapted from PRISM Study Investigators;¹ PRISM-PLUS Study Investigators;² Cannon et al;³ Blazing et al.^4
aPRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management; ^bPRISM-PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms; ^cTACTICS = Treat Angina with AGGRASTAT and Determine Cost of Therapy with an Invasive or Conservative Strategy; ^dA to Z = AGGRASTAT to ZOCOR™^† (simvastatin, MSD) Trial;
ASA = acetylsalicylic acid; UFH = unfractionated heparin

• Maintenance infusion administered at least for 48 hours
• No dosage adjustments required in patients 65 years of age or older (>40% of patients in clinical trials were >65 years)
• Can be administered to patients with mild to moderate renal insufficiency without dosage adjustment. Decrease dosage by 50% in patients with severe renal insufficiency (creatinine clearance <30 ml/min)

Please see full prescribing information for additional information.